Skip to main content


We're creating a new version of this page. See preview

  • Oral presentation
  • Open Access

Phototoxicity – from molecular descriptors to classification models

  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 1
Journal of Cheminformatics20113 (Suppl 1) :O10

  • Published:


  • Coumarin
  • Phenothiazine
  • Molecular Descriptor
  • Recursive Partitioning
  • Maximum Absorption Wavelength

Potential photoactivation of certain pharmaceuticals, cosmetic ingredients and natural products by sunlight (e.g., phenothiazines, arylsulfonamides, or coumarins) has to be considered early on in development in order to avoid serious adverse effects (for example phototoxic or photoallergic reactions). Current clinical trial registration guidelines (FDA May 2003 [1], EMEA Dec. 2002 [2]) recommend photosafety testing of molecules if they exhibit strong absorption bands between 290-700nm and if they are significantly partitioned in human skin or eyes.

The UV absorption coefficients and the tissue partitioning of a compound are considered as important factors for phototoxic effects. However, the rationalization and prediction of phototoxicity by (quantitative) structure-property relationships ((Q)SPR) offers a valuable strategy to reduce experimental testing if an appropriate precision level of the underlying model is guaranteed.

A diverse data set of known phototoxicants and non-phototoxicants including various molecular chemotypes (90 % of them are pharmaceuticals) was compiled. After geometry optimization the maximum absorption wavelength of each compound was calculated by semi-empirical methods followed by subsequent computation of molecular descriptors. Our in silico analysis (e.g., PLS and recursive partitioning) of quantum chemical as well as classical molecular descriptors (e.g., LUMO, HOMO/LUMO gap, electron affinity, ionization energy, molecular fragments, physicochemical descriptors such as logD, pKa and logPeff) has led to predictive photosafety classifiers. Model validation was performed with a proprietary external test set of an in vitro photosafety assay (3T3 neutral red assay).

Our photosafety models are currently applied in a prospective manner in the prioritization, classification and labeling of newly designed molecules.

Authors’ Affiliations

Sanofi-Aventis, R&D Frankfurt, Germany
Sanofi-Aventis, R&D Montpellier, France


  1. Food and Drug Administration: 5600 Fishers Lane, Rockville, MD 20857,,
  2. The European Agency for the Evaluation of Medicinal Products: 7 Westferry Circus, Canary Wharf, London E14 4HB,,


© Schmidt et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.